RTOG Foundation Study 3523

MOMENTUM-1

A Multicenter, Randomized, Open-Label, Phase II Study of [177Lu] Lu-Dotatate in Adults with Progressive Intracranial Grade 1-3 Meningioma 

Principal Investigators

Principal Investigator (Radiation Oncology): Erik P. Sulman, MD, PhD
Principal Investigator (Neuro-Oncology): Sylvia C. Kurz, MD, PhD

Primary Objective

To evaluate the efficacy of [177Lu] Lu-Dotatate measured by progression-free survival as compared to local standard of care therapy in adults with progressive WHO grade 1-3 meningioma that demonstrate sufficient uptake by [68Ga] Ga-Dotatate PET. 

Patient Population

Adult patients with progressive WHO grade 1-3 meningioma.